Cécile Chartier

Cécile Chartier has a diverse and extensive work experience in the field of biotechnology and pharmaceuticals. Cécile is currently serving as the Chief Scientific Officer at NextVivo since November 2022. Prior to this, in April 2022, they founded their own consulting firm called Chartier CONSULTING, where they provided research program management, project team lead, and due diligence services in the field of antibody, cell, and gene therapies for human diseases.

Before starting their consulting firm, Cécile worked as the Chief Scientific Officer at NextVivo from July 2021 to December 2021. Prior to that, they held significant roles at Iovance Biotherapeutics, Inc., where they served as the Vice President of Research from September 2017 to July 2021. In this position, they led research and translational research programs in immuno-oncology TIL therapies and clinical biomarker programs.

Earlier in their career, Cécile worked at OncoMed Pharmaceuticals as the Senior Director of Target Validation. During their tenure from January 2012 to August 2017, they led multiple projects related to antibody-based drug candidates and cancer stem cell-targeted therapeutics. Cécile also served as the Director of Target Validation, where they studied the Wnt signaling pathway and validated BMP signaling as a cancer stem cell pathway. Before joining OncoMed Pharmaceuticals, they worked as a Senior Scientist and Group Leader at the same company, where they focused on viral vector transfer methods and validated the Notch and Wnt signaling pathways as targets for cancer treatment and cancer stem cell elimination.

Cécile's career also includes their role as a Scientist III at Berlex Biosciences from March 2002 to March 2005, where they developed improved viral vectors for the treatment of cancer and Multiple Sclerosis. Cécile also managed the virus production facility. Prior to that, they worked as a Research Associate at Stanford University from December 2000 to February 2002, where they generated complementation cell lines for the production of adenovirus vectors.

Cécile began their career at Transgene in June 1993 as a Scientist, where they invented a novel method for generating recombinant adenoviral vectors. Cécile also conducted research on adenovirus 5 and its role in immune regulation.

Overall, Cécile Chartier has a wealth of experience in the biotechnology and pharmaceutical industry, with expertise in antibody, cell, and gene therapies, as well as cancer research and immunology. Cécile has held various leadership positions and made significant contributions to the development of innovative therapies.

Cécile Chartier completed their education in a chronological order, consisting of a Master's degree, a Doctor of Philosophy (PhD), and a Post-Doc. In 1987 to 1988, they obtained a Master's degree in Molecular Biology from the University of Strasbourg. Following this, they pursued further studies and obtained a Doctor of Philosophy (PhD) in Molecular Biology from the University of Strasbourg, completing it from 1989 to 1993. Finally, they attended Harvard Medical School from 1997 to 2000, where they pursued a Post-Doc and focused on Gene/Genetic Therapy.